Two years of the COVID-19 pandemic in the population of Czech patients with inflammatory bowel disease treated with biological therapy*experience of the tertiary IBD center.
Gastroenterologie a Hepatologie
; 77(1):14-20, 2023.
Article
in Czech
| EMBASE | ID: covidwho-2313487
ABSTRACT
Background:
Inflammatory bowel disease (IBD) may be associated with a more severe course of infections and a different response to vaccination, especially in complicated IBD course and in association with immune-modifying IBD treatment. The aim of this study was to describe COVID-19 pandemic during years 2020 2022 in IBD patients with long-Term biological therapy. Method(s) A retrospective analysis of SARS-CoV-2 infection incidence in the population of 1,177 IBD (Crohn s disease or ulcerative colitis) patients with long-Term biological therapy (IBD cohort) was performed. The incidence rate, crude incidence rate and standardized incidence ratio of COVID-19 in the IBD cohort, the odds ratio of infection depending on the type of biologic therapy administered, the dynamics of COVID-19 incidence depending on the predominant SARS-CoV-2 variant in the population and the current vaccination coverage of the IBD cohort were calculated. Result(s) From January 2020 to April 2022, 548 confirmed cases of COVID-19 (46.6%) were reported in the IBD cohort, with 39% share of PCR positivity in vaccinated individuals and with 95% occurrence of infection in unvaccinated part of the IBD cohort. Standardized incidence rate ratio of COVID-19 was 27% higher in the IBD cohort compared to the general Czech population. The dynamics of the development of the number of positive cases of COVID-19 in the IBD cohort was identical to the situation in the entire country. A higher odds ratio of the chances of infection was demonstrated in patients treated with tumor necrosis factor inhibitors, but not in patients treated with anti-integrins or monoclonal antibodies against interleukins. In the IBD cohort, 85.2% of patients were properly vaccinated, which was significantly more than the vaccination rate of the entire Czech population. Discussion andconclusion:
During the two pandemic years, the incidence of COVID-19 in patients with severe IBD and long-Term biological treatment was higher compared to the general Czech population, despite the favorable vaccination coverage of this high-risk patients group. A higher risk was associated with tumor necrosis factor inhibitor therapy.Copyright © 2023 Galen s.r.o.. All rights reserved.
biological therapy; covid-19; Crohn s disease; inflammatory bowel disease; SARS-CoV-2; ulcerative colitis; vaccination; article; cohort analysis; comparative study; controlled study; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; Crohn disease/dt [Drug Therapy]; Czech (citizen); human; incidence; inflammatory bowel disease/dt [Drug Therapy]; major clinical study; pandemic; retrospective study; standardized incidence ratio; ulcerative colitis/dt [Drug Therapy]; vaccinee; adalimumab/dt [Drug Therapy]; biological product/dt [Drug Therapy]; golimumab/dt [Drug Therapy]; infliximab/dt [Drug Therapy]; SARS-CoV-2 vaccine/dt [Drug Therapy]; tofacitinib/dt [Drug Therapy]; tumor necrosis factor inhibitor/dt [Drug Therapy]; ustekinumab/dt [Drug Therapy]; vedolizumab/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Czech
Journal:
Gastroenterologie a Hepatologie
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS